Dr. Anju Agarwal, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2633 Centennial Blvd Ste 100, Tallahassee, FL 32308 Phone: 850-431-5404 Fax: 850-656-3376 |
Lance Micheel Freeman, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2633 Centennial Blvd Ste 100, Tallahassee, FL 32308 Phone: 850-431-5404 Fax: 850-656-3376 |
Kristin A Harmon, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1961 Buford Blvd, Tallahassee, FL 32308 Phone: 850-702-5007 Fax: 850-219-1059 |
Luz M Prieto-sanchez, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1705 S Adams St, Tallahassee, FL 32301 Phone: 850-224-7154 Fax: 850-561-0572 |
Dr. Antoni Ramon Kafrouni Gerges, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2633 Centennial Blvd Ste 100, Tallahassee, FL 32308 Phone: 850-431-5404 |
Fabiola De Los Angeles D'ambrosio, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 2633 Centennial Blvd Ste 100, Tallahassee, FL 32308 Phone: 850-431-5404 |
Celeste Hart, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1705 S Adams St, Tallahassee, FL 32301 Phone: 850-224-7154 |
News Archive
Bunker Vein and Imaging Center is proud to announce its second location, which opened this month in Round Rock, Texas. Dr. Stephen Bunker and his medical team have been treating patients with varicose veins, spider veins and venous disease for over five years in the Central Austin area.
Researchers at the University of Cincinnati College of Medicine have shown that probenecid, a drug long used to treat gout, may be able to improve heart function in adult patients who experience heart failure.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms.
› Verified 1 days ago